Serotonin transporter gene variation and refractory mesial temporal epilepsy with hippocampal sclerosis.
We performed a molecular epidemiology study in a population of 105 mesial temporal lobe epilepsy with hippocampal sclerosis (MTE-HS) patients in order to investigate the role of a polymorphism in the serotonin transporter gene (SLC6A4) in the prediction of antiepileptic drug (AED) treatment response. Homozygous carriers of the 12-repeat allele had an almost fourfold increase in risk for a MTE-HS not responding to medical treatment (OR 3.88; CI 95% 1.40-10.7; p=0.006) compared to carriers of the 10-repeat allele. Therefore, a polymorphism of SLC6A4 might be a genetic marker of pharmacoresistance in MTE-HS patients.
Kauffman
Marcelo Andrés
MA
Centro de Epilepsia, División Neurología, Hospital Ramos Mejía, CEFYBO, CONICET, Buenos Aires, Argentina. marcelokauffman@marcelokauffman.info
Consalvo
Damián
D
Gonzalez-Morón
Dolores
D
Aguirre
Florencia
F
D'Alessio
Luciana
L
Kochen
Silvia
S
D000328:Adult; D000483:Alleles; D000927:Anticonvulsants / Q000627:therapeutic use; D004351:Drug Resistance; D004833:Epilepsy, Temporal Lobe / Q000235:genetics* / Q000473:pathology*; D005260:Female; D014644:Genetic Variation / Q000235:genetics*; D005838:Genotype; D006624:Hippocampus / Q000473:pathology*; D006801:Humans; D007438:Introns / Q000235:genetics; D008297:Male; D018598:Minisatellite Repeats / Q000235:genetics; D012306:Risk; D012598:Sclerosis; D050486:Serotonin Plasma Membrane Transport Proteins / Q000235:genetics*
D000927:Anticonvulsants; C493230:SLC6A4 protein, human; D050486:Serotonin Plasma Membrane Transport Proteins